Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

hexocyclium methylsulfate

TRAL

hexocyclium methylsulfate (TRAL) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 74
News articles 0
Drug details — hexocyclium methylsulfate
US status
approved
Class
—
Route
ORAL
Patents
20
Programs
74
Data quality
0.84
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

hexocyclium methylsulfate (TRAL) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN hexocyclium methylsulfate
Brand TRAL
Mechanism Muscarinic acetylcholine receptor M1 antagonist
Target Muscarinic acetylcholine receptor M1
Route ORAL
Formulation TABLET

Mechanism of action

Muscarinic acetylcholine receptor M1 antagonist

Primary target: Muscarinic acetylcholine receptor M1

Approval history

Authority Status Date
FDA approved —

Pipeline programs

Search pipeline
  1. Busulfan (BU) Phase 3 · First People's Hospital · Primary Central Nervous System Lymphoma
  2. D9075C00001 Phase 3 · AstraZeneca · The target population of interest in this study is participa
  3. DM199-2021-001 Phase 3 · DiaMedica Therapeutics · Acute Ischemic Stroke
  4. INTENSIFY BD Phase 3 · Disc Medicine · Bipolar depression
  5. LIPO-202 Phase 3 · Evofem Biosciences · Central Abdominal Bulging
  6. LP0162-1336 Phase 3 · LEO Pharma US · Treatment of moderate-to-severe Atopic dermatitis
  7. Ranibizumab 0.5 mg Phase 3 · Novartis India · Central Retinal Vein Occlusion
  8. SPD465-303 Phase 3 · Takeda · Attention Deficit Disorder With Hyperactivity

Related & competitor drugs

Browse all drugs
  1. atropine sulfate Sensory organs (S01)
  2. benztropine mesylate Muscarinic acetylcholine receptor M1 antagonist
  3. dicyclomine hydrochloride Muscarinic acetylcholine receptor M3 antagonist
  4. glycopyrrolate Muscarinic acetylcholine receptor M3 antagonist
  5. pilocarpine hydrochloride Muscarinic acetylcholine receptor M3 agonist
  6. scopolamine Muscarinic acetylcholine receptor M1 antagonist

Related patents

Browse patents

  1. US 12422364

    Fluorescence spectral shape analysis for analyte recognition

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12351653

    Pharmaceutical compositions comprising novel cyclic peptides

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12329457

    Hyperspectral imaging for early detection of Alzheimer's disease

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12331105

    Broadly neutralizing antibodies against HIV

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. WO 2025096967

    REDIRECTION DE CAPSIDES D'AAV POUR CIBLAGE DU SYSTÈME NERVEUX CENTRAL

    Expires Wed May 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12274735

    IL-4-fusion formulations for treatment of central nervous system (CNS) tumors

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12269872

    Neutralizing antibodies to Plasmodium falciparum circumsporozoite protein and their use

    Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12202886

    Neutralizing antibodies to GP120 and their use

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12156912

    Methods and compositions for inhibiting diseases of the central nervous system

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12146150

    Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12110334

    Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12103907

    Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12098152

    Methods and compositions for treating polycystic ovary syndrome

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12043660

    10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use

    Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11976109

    Neutralizing antibodies to ebola virus glycoprotein and their use

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11939370

    Pan-ebola virus neutralizing human antibodies and methods of use therefor

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11884718

    Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following ZIKV infection or vaccination

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11858932

    Methods and compositions for treating polycystic ovary syndrome

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11851481

    Treatment of central nervous system disorders by intranasal administration of immunoglobulin g

    Expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11819276

    Hyperspectral imaging for early detection of Alzheimer's disease

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is hexocyclium methylsulfate?

hexocyclium methylsulfate (TRAL) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for hexocyclium methylsulfate?

TRAL is a marketed brand name for hexocyclium methylsulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of hexocyclium methylsulfate?

hexocyclium methylsulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.